SCHEMBL20140226

SCHEMBL20140226

COc1cc(F)c(C2(O)O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@H](OCc3ccccc3)[C@H]2OCc2ccccc2)cc1Cc1ccc2c(c1)CC2

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC5A1 P13866 10/20 0.45
SLC5A2 P31639 10/20 0.45
BACE1 P56817 1/20 0.33
PTPN1 P18031 2/20 0.33
AADAT Q8N5Z0 1/20 0.31
SSTR1 P30872 1/20 0.31
SSTR2 P30874 1/20 0.31
SSTR4 P31391 1/20 0.31
SSTR3 P32745 1/20 0.31
SSTR5 P35346 1/20 0.31
TP53 P04637 1/20 0.31
MDM2 Q00987 1/20 0.31
PTPN2 P17706 1/20 0.31
PTPN11 Q06124 1/20 0.31
OPRM1 P35372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20141619 0.91 SLC5A1 (0.43) SLC5A1SLC5A2PTPN1SSTR1SSTR2
SCHEMBL20140181 0.91 SLC5A1 (0.41) SLC5A1SLC5A2PTPN1
SCHEMBL20140115 0.89 SLC5A1 (0.39) SLC5A1SLC5A2PTPN1
SCHEMBL20139450 0.89 SLC5A2 (0.42) SLC5A1SLC5A2PTPN1TP53MDM2
SCHEMBL20140047 0.88 SLC5A1 (0.35) SLC5A1SLC5A2PTPN1TP53MDM2
SCHEMBL20139464 0.83 SLC5A1 (0.38) SLC5A1SLC5A2PTPN1PTPN2PTPN11
SCHEMBL20140088 0.83 SLC5A1 (0.38) SLC5A1SLC5A2PTPN1PTPN2PTPN11
SCHEMBL20140244 0.83 SLC5A1 (0.40) SLC5A1SLC5A2PTPN1PTPN2PTPN11
SCHEMBL20140224 0.82 SLC5A2 (0.39) SLC5A1SLC5A2PTPN1PTPN2PTPN11
SCHEMBL20139387 0.82 SLC5A1 (0.38) SLC5A1SLC5A2PTPN1TP53MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 SLC5A1 2/4885SLC5A2 1/4885BACE1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.